Drugs / CPT-11 (Irinotecan)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01996306 | Dec 2013 → Nov 2017 | colorectal neoplasm, metastatic malignant neoplasm | Epidemiological and Clinical Research Information Network | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPT-11 (Irinotecan) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01996306 ↗ |
| Route | Intravenous | “150-180 mg/m2 intravenously administered over 90 minutes” NCT01996306 ↗ |